These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17139193)

  • 1. Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development.
    Nizri E; Irony-Tur-Sinai M; Grigoriadis N; Abramsky O; Amitai G; Brenner T
    Pharmacology; 2007; 79(1):42-9. PubMed ID: 17139193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein.
    Irony-Tur-Sinai M; Grigoriadis N; Lourbopoulos A; Pinto-Maaravi F; Abramsky O; Brenner T
    Exp Neurol; 2006 Mar; 198(1):136-44. PubMed ID: 16423348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herbal complement inhibitors in the treatment of neuroinflammation: future strategy for neuroprotection.
    Kulkarni AP; Kellaway LA; Kotwal GJ
    Ann N Y Acad Sci; 2005 Nov; 1056():413-29. PubMed ID: 16387706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurogenic mechanisms in bronchial inflammatory diseases.
    Groneberg DA; Quarcoo D; Frossard N; Fischer A
    Allergy; 2004 Nov; 59(11):1139-52. PubMed ID: 15461593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches.
    Prandota J
    Am J Ther; 2007; 14(1):63-105. PubMed ID: 17303977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity.
    Yun TJ; Harning EK; Giza K; Rabah D; Li P; Arndt JW; Luchetti D; Biamonte MA; Shi J; Lundgren K; Manning A; Kehry MR
    J Immunol; 2011 Jan; 186(1):563-75. PubMed ID: 21131419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autoimmune dermatoses: new therapeutic strategies].
    Trüeb RM
    Praxis (Bern 1994); 2000 Sep; 89(37):1460-7. PubMed ID: 11037617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW; Akimova T; Beier UH; Liu Y; Wang L
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i46-54. PubMed ID: 22460138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
    Norman P
    Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal antibodies in chronic autoimmune inflammatory diseases].
    Semerano L; Boissier MC
    Med Sci (Paris); 2009 Dec; 25(12):1108-12. PubMed ID: 20035687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network medicine in drug design: implications for neuroinflammation.
    Ghosh S; Basu A
    Drug Discov Today; 2012 Jun; 17(11-12):600-7. PubMed ID: 22326234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copolymer 1 from the laboratory to FDA.
    Teitelbaum D; Sela M; Arnon R
    Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunosuppressive activity of a novel peptide analog of α-melanocyte stimulating hormone (α-MSH) in experimental autoimmune uveitis.
    Edling AE; Gomes D; Weeden T; Dzuris J; Stefano J; Pan C; Williams J; Kaplan J; Perricone MA
    J Neuroimmunol; 2011 Jul; 236(1-2):1-9. PubMed ID: 21640392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T lymphocyte line-mediated experimental allergic encephalomyelitis--a pharmacologic model for testing of immunosuppressive agents for the treatment of autoimmune central nervous system disease.
    Westarp ME; Wekerle H; Ben-Nun A; Cohen IR; Vohl ML; Przuntek H
    J Pharmacol Exp Ther; 1987 Aug; 242(2):614-20. PubMed ID: 3497261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis].
    Jolliet P
    Rev Neurol (Paris); 2000 Jul; 156(6-7):681-3. PubMed ID: 10891808
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW
    Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthritis in MRL/LPR mice and in collagen II sensitized DBA-1 mice and their use in pharmacology.
    Rordorf C; Pataki A; Nogues V; Schlager F; Feige U; Glatt M
    Int J Tissue React; 1987; 9(4):341-7. PubMed ID: 3623829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator.
    van Eden W
    Curr Opin Investig Drugs; 2008 May; 9(5):523-33. PubMed ID: 18465663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.